Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
ITRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $3.02
Previous CloseN/A
Volume220.96K
Average Volume (3M)694.71K
Market Cap
$29.88M
Enterprise Value$59.27M
Total Cash (Recent Filing)$13.03M
Total Debt (Recent Filing)$32.56M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 07, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding44,656,906
10 Day Avg. Volume698,929
30 Day Avg. Volume694,711
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-46.41
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$5.00Price Target Upside646.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market OpportunityORLYNVAH targets uncomplicated urinary tract infections with exclusivity in the US until 2034, creating a significant market opportunity for Iterum.
Product LaunchIterum Therapeutics has introduced ORLYNVAH, the first oral penem approved in the US, which addresses a long-standing demand for a safe and effective oral option in the penem class of antibiotics.
Strategic PartnershipsIterum's strategic and targeted approach in launching ORLYNVAH is supported by partnerships with Eversana and Alto Specialty Pharmacy, which enhances their sales and logistics capabilities.
Bears Say
CompetitionThe presence of competing products from companies like GSK in the uUTI market may influence Iterum's stock performance, although ORLYNVAH remains a more attractive therapeutic option.
Iterum Therapeutics News
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.61 and its highest was $3.02 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Iterum Therapeutics Plc’s market cap is $29.88M.
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is Nov 07, 2025 which is in 34 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on Aug 05, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.02.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -0.09.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 44,656,906 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -1.408%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Currently, no hedge funds are holding shares in ITRM
Iterum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (646.27% Upside)
$5.00 (646.27% Upside)
Insider Transactions
Bought Shares
Worth $10.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.88%
12-Months-Change
Fundamentals
Return on Equity
607.06%
Trailing 12-Months
Asset Growth
139.97%
Trailing 12-Months
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics (ITRM) is a clinical-stage pharmaceutical company focused on developing innovative anti-infectives aimed at combating antibiotic-resistant pathogens. The company's primary product candidate, sulopenem, is a novel, oral and intravenous penem antibiotic intended for the treatment of multi-drug resistant infections, including those caused by Gram-negative and Gram-positive bacteria. Iterum operates within the biotechnology and pharmaceutical industry sectors, emphasizing the development and commercialization of treatments for serious bacterial infections.
ITRM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress with the early launch of ORLYNVAH, a large addressable market, secured manufacturing, extended financial flexibility, and strong market protection. However, increased operating expenses, rising net loss, and the need for additional share authorization highlight financial challenges. There is a balanced sentiment with notable achievements and challenges.View all ITRM earnings summariesITRM Stock 12 Month Forecast
Average Price Target
$5.00
▲(646.27% Upside)
Technical Analysis
Cel-Sci
―
Clene
―
Xilio Therapeutics
―
CAMP4 Therapeutics Corporation
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
1.30% Insiders
0.03% Mutual Funds
2.68% Other Institutional Investors
95.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---